Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)
 
 • Company Description   
Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

Number of Employees: 385

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.01 Daily Weekly Monthly
20 Day Moving Average: 1,407,560 shares
Shares Outstanding: 88.81 (millions)
Market Capitalization: $1,332.96 (millions)
Beta: 0.72
52 Week High: $25.29
52 Week Low: $7.72
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.02% -6.38%
12 Week 3.52% -11.58%
Year To Date -13.84% -19.29%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3611 VALLEY CENTRE DR SUITE 300
-
SAN DIEGO,CA 92130
USA
ph: 888-969-7879
fax: 302-645-1280
ir@travere.com https://travere.com
 
 • General Corporate Information   
Officers
Eric Dube - Chief Executive Officer
Gary Lyons - Chairman
Christopher Cline - Chief Financial Officer
Sandra Calvin - Senior Vice President and Chief Accounting Officer
Roy D. Baynes - Director

Peer Information
Travere Therapeutics, Inc. (CORR.)
Travere Therapeutics, Inc. (RSPI)
Travere Therapeutics, Inc. (CGXP)
Travere Therapeutics, Inc. (BGEN)
Travere Therapeutics, Inc. (GTBP)
Travere Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89422G107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 88.81
Most Recent Split Date: (:1)
Beta: 0.72
Market Capitalization: $1,332.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.31 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 40.61
Price/Cash Flow: -
Price / Sales: 4.87
EPS Growth
vs. Year Ago Period: 73.30%
vs. Previous Quarter: 35.62%
Sales Growth
vs. Year Ago Period: 97.54%
vs. Previous Quarter: 9.29%
ROE
06/30/25 - -
03/31/25 - -1,179.73
12/31/24 - -1,088.35
ROA
06/30/25 - -
03/31/25 - -41.10
12/31/24 - -55.44
Current Ratio
06/30/25 - -
03/31/25 - 2.05
12/31/24 - 2.08
Quick Ratio
06/30/25 - -
03/31/25 - 2.03
12/31/24 - 2.04
Operating Margin
06/30/25 - -
03/31/25 - -82.58
12/31/24 - -137.51
Net Margin
06/30/25 - -
03/31/25 - -82.88
12/31/24 - -137.90
Pre-Tax Margin
06/30/25 - -
03/31/25 - -82.60
12/31/24 - -137.46
Book Value
06/30/25 - -
03/31/25 - 0.37
12/31/24 - 0.76
Inventory Turnover
06/30/25 - -
03/31/25 - 1.94
12/31/24 - 1.34
Debt-to-Equity
06/30/25 - -
03/31/25 - 9.46
12/31/24 - 5.25
Debt-to-Capital
06/30/25 - -
03/31/25 - 90.44
12/31/24 - 84.01
 

Powered by Zacks Investment Research ©